Healthcare Technology / Precision Medicine / Data-Driven Diagnostics
Strategic Profile
SOPHiA DDM™ Platform is one of the largest technology-agnostic networks of connected healthcare institutions worldwide and is currently used by more than 750 hospital, laboratory, and biopharma institutions globally. In March 2025, the company announced it had hit the milestone of 2 million genomic profiles analysed with its Sophia DDM platform.
Cyborg Score Rationale
SOPHiA GENETICS has strong platform traction with 2M genomic profiles analyzed and 750+ institutional users, supported by marquee partnerships with Memorial Sloan Kettering, AstraZeneca, and GE Healthcare. However, profitability remains challenged with negative EPS of -$1.12 and a declining stock price ($5.34 as of Feb 2026), suggesting execution or market concerns.
Top Insights
2M genomic profiles analyzed as of March 2025 demonstrates significant platform traction and network effects in data-driven diagnostics
750+ institutional users across hospitals, laboratories, and biopharma firms represent broad market penetration and switching costs
Strategic partnerships with Memorial Sloan Kettering, AstraZeneca, GE HealthCare, Qiagen, and Hitachi validate market relevance and accelerate adoption
Trailing twelve-month revenue of $73.3M shows steady growth but company remains unprofitable (-$1.12 EPS), requiring operational optimization
Named Competitors
Flatiron Health — Oncology-focused EHR and data analytics platform
DNAnexus — Cloud-based genomics data management and analysis
Benchling — Research operations and data management platform
Agilent Technologies — Genomics instrumentation and software solutions